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Michael J. Welch, Ph.D., Recipient of the Aebersold Award 
Aebersold Award To Dr. Michael J. Welch 
Note from the Director of Mallinckrodt Institute, Ronald G. 
Evens, M.D. 
The following article announces the awarding of a presti- 
gious honor to Michael J. Welch, Ph.D., Professor of Radiology 
at the Mallinckrodt Institute and Washington University. This 
is the highest recognition for science bestowed by the Society 
of Nuclear Medicine. Mike Welch's recognition is well-deserved 
because of his many contributions to the development of 
short-lived radiopharmaceuticals, their clinical use, and the 
training of many scientists in this field. The Mallinckrodt 
Institute and Washington University take great pride in the 
recognition of Dr. Welch and are particularly pleased that two 
of only eight recipients of the Aebersold Award are from this 
Institution. 
The Society of Nuclear Medicine has honored Dr. 
Michael J. Welch, Professor of Radiology and Chem- 
istry at Mallinckrodt Institute and Washington Uni- 
versity for his pioneering role as the first hot-atom 
chemist to become involved in using a cyclotron to 
make very short-lived radio-pharmaceuticals for nu- 
clear medicine. Dr. Welch is the recipient of the 
Society's prestigious Paul C. Aebersold Award which 
was presented to him at the 27th annual meeting of 
the Society of Nuclear Medicine, June 24-27, in 
Detroit. 
The Society of Nuclear Medicine is an organization 
of more than 10,000 physicians, scientists, and 
technologists. In selecting Dr. Welch, the awards 
committee took into consideration not only his 
extensive research contributions in radiopharmaceu- 
tical chemistry, but also his equally noteworthy 
efforts in clinical research, patient care, and teaching. 
Other recipients, since the award was first pre- 
sented in 1973, include Dr. Michel Ter-Pogossian 
(1976) for the development of the Positron Emission 
Transverse Tomography (PETT) system, making Mal- 
linckrodt the only medical institution with two 
recipients. This year, the award includes a plaque of 
citation praising Dr. Welch for his outstanding 
achievements in basic science applied to nuclear 
medicine. 
Dr. Welch was awarded the B.A. and M.A. degrees 
from Cambridge University, England. In 1965, having 
received his Ph.D. degree on the chemistry of hot| 
tritium atoms from the University of London, he 
went on to Brookhaven National Laboratory to begin 
a two year fellowship with Alfred P. Wolf, studying 
the chemistry of hot carbon atoms. Entering the field 
of nuclear medicine in 1967, when he joined the staff 
of Mallinckrodt Institute of Radiology, Dr. Welch 
began an effective, far-sighted program of research 
involving short-lived cyclotron-produced radio 
pharmaceuticals. As a result, the Institute can count 
several firsts in the clinical use of positron emitters. 
Dr. Welch's early research led to the production of 
simple molecules synthesized directly in the cyclo 
tron target, but by utilizing clever techniques, he 
soon was able to synthesize more complex radiophar 
maceuticals for application in nuclear medicine. His 
C-glucose for the measurement of cerebral metabo 
lism synthesis represents a benchmark study ir 
nuclear medicine. For the first time, a cyclotron was 
used to prepare a precursor which was used foi 
biosynthesis of a complex molecule. 
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During the past decade, one of the most important 
products developed in Dr. Welch's laboratory has 
been C-methylputrescine, the first positron emitting 
radiopharmaceutical for tumor location, which has 
been used successfully in detecting carcinoma. 
The C-palmitate developed in Dr. Welch's labora- 
tory is another radiopharmaceutical involving new 
and creative cyclotron radiochemistry and is now 
being used for routine diagnostic PETT imaging, and 
for the measurement of myocardial metabolism. 
Demonstrating the clinical efficacy of radiopharma- 
ceuticals such as these, Dr. Welch has facilitated the 
transition of nuclear medicine away from the deter- 
mination of organ structure towards the measurement 
of organ function. 
Washington University has been a Specialized 
Center of Research for thrombosis for ten years, and 
one major area of achievement has been the success 
of Dr. Welch and his co-workers in developing 
pharmaceuticals for studying coagulation disorders. 
The ln-111 research at Mallinckrodt Institute revolu- 
tionized the methodology for labeling cells and 
introduced a whole new class of radiopharmaceuticals 
to nuclear medicine. Presently, many other labora- 
tories are imitating Dr. Welch's research program 
involving the use of 111 In-platelets for imaging 
thrombi and 111 In-leukocytes to detect abscesses 
and measure inflammatory response in ischemic 
myocardium. 
Early in 1970, Dr. Welch began to develop an 
interdisciplinary teaching program which today at- 
tracts students from across the United States. Prior to 
its initiation, a career in radiopharmaceutical chemis- 
try required a Ph.D. degree in hot atom chemistry 
followed by an applied post-doctoral fellowship in a 
clinical environment. Dr. Welch, in seeking a joint 
appointment at Washington University in both radi- 
ology and chemistry, altered the educational patterns 
of radiopharmaceutical scientists, demonstrated that 
the principles of radiochemistry and radiopharma- 
ceutical chemistry could be part of one integrated 
program, and served as an early role model for the 
interdisciplinary scientist who applies the rigor of 
basic science to the solution of practical clinical 
problems. 
Having worked in Dr. Welch's laboratory as a 
post-doctoral fellow, Kenneth A. Krohn, Ph.D., Asso- 
ciate Professor of Radiology and Acting Director of 
Nuclear Medicine at the University of California, 
Davis, comments in a letter supporting the nomina- 
tion on the dominant role Dr. Welch has played in 
training graduate students, post-doctoral fellows, nu- 
clear medicine residents, and sabbatical academicians. 
Included among those scientists are Michael D. 
Loberg, Ph.D., Director of Pharmaceutical Research, 
Squibb Institute; John Harwig, Ph.D., Associate 
Professor, U.S.C.; Mathew Thakur, Ph.D., Associate 
Professor, Yale University; Linda Knight, Ph.D., 
Associate Professor, Temple University; and James 
Frost, M.D., Ph.D., Johns Hopkins University. 
Pictured right are former students 
and colleagues of Dr. Welch. Left to 
right are: Linda Knight, Ph.D., 
Temple University; Barbara Francis, 
George Washington University; Wil- 
liam Eckelman, Ph.D., George 
Washington University; Mathew 
Thakur, Ph.D., Yale University; 
Maria Straatman, M.S., Cyclotron 
Corporation; and Kenneth Krohn, 
Ph.D., University of California. 
Aebersold Award 
The Paul C. Aebersold Award honors the memory 
of a man who was responsible more than any other 
individual for the acceptance and application of 
radioisotopes in this country. Dr. Aebersold was a 
member of a group of scientists under Professor 
Ernest Lawrence at Berkeley who developed the 
cyclotron in the early 1930s. He later participated in 
the production and application of the first radioactive 
material administered to human beings. Assigned to 
radioisotope production on the Manhattan Project 
during World War II and the subsequent development 
of the atomic bomb. Dr. Aebersold directed the first 
peaceful distribution and use of radioisotopes at Oak 
Ridge, Tennessee. In 1946, Mallinckrodt Institute of 
Radiology shared in the use of an isotope for cancer 
research when the first unit of radioactive Carbon-14 
was released by the War Department to Barnard Free 
Skin and Cancer Hospital. When Dr. Aebersold retired 
as Director of the AEC Division of Isotopes Develop- 
ment in 1965, as a result of his efforts, radioisotopes 
had been applied in the fields of biology, medicine, 
industry, agriculture, and many others. 
The hallmarks of Dr. Michael Welch's career as a 
research scientist—the importance of a good scientific 
background, the need to be scientifically adventur- 
ous, and above all a propensity for continuing 
education—represent a fitting tribute to the memory 
of Paul C. Aebersold. 
Elected to 
Executive Council 
Dr. Ronald G. Evens, Elizabeth Mallinckrodt Pro- 
fessor and Director of the Mallinckrodt Institute of 
Radiology, Washington University^ School of Medi- 
cine, has been elected for a five-year term to the 
Executive Council of the American Roentgen Ray 
Society. 
The twenty-member Council is the governing body 
of the Society and includes the officers, the chairmen 
of key committees, and five elected members. 
The oldest of the American scientific radiological 
organizations, the American Roentgen Ray Society 
was founded in 1900 in St. Louis with the objective 
of advancing medicine through the science of radiol- 
ogy. It gives particular emphasis to significant teach- 
ing efforts and contributions of members to medical 
literature. 
Dr. Evens was appointed head of the Department 
of Radiology at Washington University in 1971. He is 
past president of the Society of the Chairmen of 
Academic Radiology Departments, a Fellow of the 
American College of Radiology, and past president of 
the Missouri Radiological Society. 
Dr. Lin Awarded Grant 
Dr. Hsiu-san Lin of the Division of Radiation 
Oncology has been awarded $448,053 from the 
National Heart, Lung, and Blood Institute to con- 
tinue his investigation on the biology of pulmonary 
alveolar macrophages for the next five years. Dr. Lir 
also received a new three-year grant totalinc 
$126,220 from the National Institute of Allergy anc 
Infectious Diseases to study the origin and differen 
tiation of blood monocytes. 






1980 Gridiron Proceeds 
For Cancer Research at MIR 
Ms. Nancy Belt, 1979-80 President of the Advertising Federation of St. Louis, presents the proceeds of the Gridiron 
Show to Mr. Edwin B. Meissner, Jr., President of the Board of Directors, Barnard Hospital. 
"Grand Slams," the 46th annual Gridiron Show of 
the Advertising Federation of St. Louis, roasting local 
personalities and poking fun at the happenings of the 
previous year, was staged on March 26, in the 
Khorassan Room of the Chase Park Plaza Hotel. The 
gala event raised $13,000 for the Barnard Free Skin 
and Cancer Hospital, and the funds will be used for 
further development of the flow-cytometry facility 
operated by the Mallinckrodt Institute Division of 
Radiation Oncology, Section of Cancer Biology. This 
intriguing new technology, which automatically 
identifies and separates different types of cells in a 
tissue sample, will greatly speed up the evaluation of 
new cancer treatments that may be used in future 
patients. 
Ms. Nancy Belt, 1979-80 AFSL President, made 
the presentation to Edwin B. Meissner, Jr., Chairman 
of the Barnard Hospital Board, at a dinner on May 6, 
at Stan and Biggies restaurant. 
Dr. Carlos Perez, Director 
of the Division of Radiation 
Oncology at Mallinckrodt 
Institute, gave a short slide 
presentation describing the 
research projects planned 
for the flow-cytometry fa- 
cility. 
The total AFSL donation 
to cancer research, since 
1945, amounts to over 
$426,000 and, according to Henrietta Meier, Gridiron 
general chairman, the funds raised have been seed 
money for matching grants resulting in more than $1 
million in contributions to local cancer research. 
AFSL's. 207-membership includes individuals with 
interests in advertising and public relations. 
FLOW CYTOMETRY 
New Technology Holds Possibilities for Cancer Research 
The Section of Cancer Biology, Division of Radiation 
Oncology has recently purchased a Becton-Dickinson, fluores- 
cent-activated cell sorter (Flow Cytometer). This was made 
possible with a generous contribution from the Advertising 
Federation of St. Louis. The Flow Cytometer is the heart of 
an extensive and newly constructed Flow Cytometry Facility 
at 4511 Forest Park Blvd. that is under the direction of Dr. 
Alexander Nakeff. The total cost of the unit is $125,000 and 
the computer capabilities required to process and analyze the 
data are worth an additional $75,000. In addition, the 
operation of this facility will cost $94,000 per year. 
The Division and Washington University School of Medicine 
have firmly committed themselves to the development of this 
sophisticated technology, which will greatly contribute to the 
cancer research program at Washington University. 
Flow cytometry is a new and exciting technology which 
applies the most recent advances in electronics and laser 
technology to the solution of some of the most basic problems 
of cell and tumor biology. A cell suspension must first be 
mixed with various fluorescent probes (either dyes or labeled 
proteins, for example) which either bind to the membranes of 
specific cells of interest or enter them to bind to specific 
internal structures such as their nuclei. The cells are then 
introduced into the machine in a stream and pass one-by-one 
through a laser beam at the rate of thousands of cells per 
second. Only those cells containing the dye are excited to emit 
a pulse of light. The signal is detected by photo-sensors which 
convert this into an electrical signal for storage into computer 
memory. Subsequently, the cell stream is charged and broken 
into droplets. Only individual droplets containing a single 
fluorescently-tagged cell are electically charged and are de- 
flected into collection vessels. Cell analysis and sorting occurs 
at rates in excess of 1000 cells per second. The Flow 
Cytometer can examine up to 3 parameters per cell simul- 
taneously with an extension to 5 parameters being readily 
available. All of the analysis and sorting can also be done 
without affecting the viability of the cells collected. 
There are a number of major areas where flow cytometry 
will have an immediate and substantial impact on the 
Divisions' cancer research program. One involves the analysis 
of different cell subpopulations which are responsible for tumor 
growth within both human and experimental solid tumors. 
These can now be separated by flow cytometry based upon 
their unique staining characteristics with various fluorescent 
probes. They are being studied following either radiation or 
drugs or their combination to determine which anticancer 
treatments are most effective in arresting tumor growth in the 
development of new and better treatments for cancer. 
Many anticancer drugs kill tumor cells most efficiently 
when the cells are in a drug-sensitive part of their life cycle. 
One of the major strategies in chemotherapy is to use two 
drugs in combination. The first drug kills some of the cells, but 
also arrests the remaining cells in a phase where they will be 
sensitive to a second drug. Flow cytometry with DNA staining 
and life cycle analysis is being used to determine which cells 
were killed by the first agent and, therefore, which cells 
comprise the target populations for the second agent. This 
information will enable lower doses of drugs to be adminis- 
tered while maintaining high levels of tumor cell killing and 
thus contribute significantly to improved combination anti- 
cancer drug therapy. 
A number of human tumors such as from breast, uterus and 
prostate are dependent upon specific hormones for their 
growth. Prior to the advent of flow cytometry, it was no; 
possible to isolate those tumor cells that were hormone-sensi- 
tive even though their presence in the tumor and their content 
of specific hormone receptors was known. The development of 
fluorescently-tagged hormones such as estrogen and proges- 
terone permits detailed studies of their binding to those target 
tumor cells expressing the appropriate receptors. Furthermore, 
the isolation of these cells by flow cytometry and their growth 
in tissue culture is being used to determine whether they are 
the same cells responsible for the growth of the tumor. 
Immunotherapy is a promising area of cancer research that 
involves studies of our body's normal defense against malig- 
nant cell growth with the goal of boosting this anticancer 
action to eradicate tumors completely. Flow cytometry 
together with the development of many highly-specific mem- 
brane labels for a host of different types of immune cells is 
making possible for the first time detailed studies of their 
interaction with malignant cells within tumors. 
It is clear that potential applications of the technology are 
multiple, being restricted solely by scientific ingenuity. Flow 
cytometry is so new and different from conventional methods 
of cell analysis that the full realization of its potential 
presently lags behind its capabilities. 
Multiparameter cell analysis is bringing together cell biolo- 
gists and clinicians as well as physicists and computer experts 
in an increasing number of the leading research and treatment 
centers in the world that now have this capability. The new 
Flow Cytometry Facility places us on the leading edge of new 
developments in this important area. It serves as a focus for 
many of the activities and interests of the Division of 
Radiation Oncology and creates opportunities for fruitful 
collaboration with researchers throughout Washington Univer- 
sity. Since the Flow Cytometry Facility is the first of its kind 
in the Bi-state region, provisions have been made for sharing 
this important resource and facility with other cell biologists 
and clinical oncologists throughout this region. 
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International Symposium 
Michael J. Welch, Ph.D., Professor 
of Radiology and Chemistry at the 
Mallinckrodt Institute of Radiology, 
was Chairman of the Third Inter- 
national Symposium on Radiophar- 
maceutical Chemistry, hosted by 
Washington University, June 16-20. 
Over two hundred participants from 
twenty three countries, including such 
distant points as Peking, Baghdad, 
Australia, and South Africa attended. 
Papers were presented on topics that 
included: all aspects of radiopharma- 
ceutical design and preparation, rele- 
vant aspects of radionuclide research 
and methodology; problems arising 
from the use of radionuclides in 
biochemical and biological studies; 
and quality control problems relating 
to   short-lived   radiopharmaceuticals. 
Others from Mallinckrodt Institute 
working with Dr. Welch on the organ- 
izing committee were Diane Zaltsman, 
Secretary-Treasurer, Dr. M.M. Ter- 
Pogossian, and Dr. T.J. Tewson. In 
addition to the scientific lecture and 
poster sessions, the committee plan- 
ned a social program for the partici- 
pants and their families that ac- 
quainted them with the St. Louis area 
and provided them with a taste of its 
rich history. 
The remarks of Dr. Welch bring smiles to the members of the Founding 
Committee of the Radiopharmaceutical Council at the Third Interna- 
tional Symposium of Radiopharmaceutical Chemistry. Left to right are: 
D.J. Silvester, Ph.D.; A.P. Wolf, Ph.D.; G. Stdcklin, Ph.D.; M.J.Welch, 
Ph.D.; I. Cohen, Ph.D.; J.G. Cunningham, Ph.D., invited speaker; and T. 
Nozaki, Ph.D. 
Dr. M. Maida, Visiting Professor in Radiation Sciences, 
right, and Dr. Kojima, Professor of Radiopharmaceutical 
Chemistry at Kyushu University, Fukuoka, Japan, enjoy 
a barbecue at Wohl Center. 
Dr. Michael J. Welch escorts Bo-Li Liu, Associate 
Professor of Radiochemistry at Peking Normal Univer- 
sity, Peking, China, and a participant in the Third 
International Symposium on Radiopharmaceutical 
Chemistry on a tour of his laboratory facilities at MIR. 
INTERVENTIONAL RADIOLOGY at MIR 
,fc   I 
Mallinckrodt Institute radiologists are performing 
many new interventional radiologic procedures, some 
of which may replace surgery. Either alone or as an 
adjunct to a surgical procedure, many of these newer 
techniques offer the possibility of treating certain 
disease situations in less time and with less risk, 
discomfort, or cost to the patient. Angioplasty, Local 
Thrombolytic Therapy, Arterial Embolization, and 
Transhepatic Biliary Drainage are all non-surgical 
therapeutic procedures which are extensions of basic 
angiographic procedures in use for decades. 
Angioplasty 
Angioplasty, the balloon catheter method for 
opening atherosclerotic arteries blocked with plaque, 
is an extension of angiography, a procedure used to 
locate, identify, and measure arterial disease. The first 
balloon catheter for treating atherosclerotic periph- 
eral vascular disease was introduced by Charles 
Dotter in 1964 and demonstrated the potential of the 
technique in treating arterial obstructions. In the 
mid-1970's, Dr. Andreas Gruntzig of Switzerland 
modified and refined the Dotter catheter by develop- 
ing a balloon that could be inflated in a controlled 
fashion to a predetermined size. Griintzig's modifica- 
tion was the breakthrough that has made percutan- 
eous balloon angioplasty possible today. 
In the last two years, Mallinckrodt radiologists Drs. 
Louis Gilula, Bruce McClennan, along with Drs. 
William Totty and Robert Stanley have performed 
over 60 peripheral and renal angioplasty procedures. 
Dr. Philip Ludbrooke anticipates the use of coronary 
angioplasty in the near future. 
Dr. Gilula explained the diagnostic procedure: 
"The radiologist inserts a catheter into the femoral 
artery and, under fluoroscopic guidance, positions it 
near the site of the stenosis or blockage. Angioplasty 
is then performed to open the vessel." Dr. Gilula 
considers the ideal candidate for peripheral angio- 
plasty as "one with peripheral vascular disease who 
experiences leg pain after walking less than one block, 
or has a non-healing foot or ankle ulcer." Dr. McClen- 
nan describes the ideal candidate for renal angioplasty 
as "someone with documented renal vascular hyper- 
tension caused by renal artery stenosis." "Angio- 
plasty may be performed in older patients to preserve 
renal function." said Dr. McClennan. 
Angiogram shows occlusion of popliteal artery with small 
collateral vessels filling the distal leg. 
For angioplasty, the radiologist threads a catheter 
equipped with a balloon that will be inflated to a 
pre-determined controlled diameter when it reaches 
the blockage in order to compress the plaque and 
stretch the blood vessel to its former diameter. The 
balloon is then deflated and blood pressure is 
measured at the site to determine whether or not the 
newly created opening affords adequate blood flow; 
if not, the angioplasty procedure can be repeated. 
"The effect is usually evident immediately," said Dr. 
Gilula. "Patients with peripheral vascular disease 
experience relief of pain, may walk the next day, and 
are usually out of the hospital in three days." 
According to Dr. McClennan, renal vascular disease 
patients often show improved blood pressure on the 
treatment table and can be out of the hospital in two 
to four days. After treatment, continued small daily 
doses of aspirin help to offset any tendency to clot. 
In a study reported by Gruntzig et al, 87 percent of 
the patients with good initial treatment results have 
their treated artery still open after two or more years. 
If the condition recurs, the patient can be re-treated 








Thrombolytic Therapy Transcatheter Arterial Embolization 
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Until recently, when angiography revealed that 
arterial obstruction was due to a clot or thrombus, 
treatment usually involved immediate surgical re- 
moval—a method not always technically feasible. 
Recently at Mallinckrodt Institute, Drs. Gilula, 
McClennan, and Totty have begun to treat selected 
patients with a new local intravascular method of 
Thrombolytic Therapy. Dr. Totty explained, "This 
method involves placing a catheter into the blocked 
artery. With the catheter tip just above or into the 
thrombus, very small amounts of a clot dissolving 
drug (streptokinase or urokinase) are directly infused. 
By using small amounts of the drug many of the 
problems associated with generalized intravenous 
treatment can be avoided. Several patients have now 
been successfully treated, including one patient with 
a totally blocked distal aorta." 
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After a 24-hour streptokinase infusion, the vessel has 
opened and the area of narrowing is again seen. An 
angioplasty was subsequently performed. The patient is 
now doing well after four months. 
Since 1975, using an interventional method called 
Transcatheter Arterial Embolization, Dr. Robert 
Stanley and Dr. William Murphy have collaborated on 
the therapeutic treatment of over a dozen patients 
with a variety of soft tissue malformations ranging 
from lesions in the pelvis to lesions in the tip of the 
finger. The malformations, clusters of abnormal 
vessels developed into a communication between an 
artery and a vein, are unusual lesions that sometimes 
behave like tumors, but are actually benign non- 
tumorous entities. "They are usually congenital in 
origin or develop following penetrating trauma such 
as a gunshot wound," said Dr. Stanley. "After 
diagnosis by arteriography, we place a catheter 
directly into the feeding vessels, then inject minute 
particles of thrombogenic material into the bed of the 
arteriovenous malformation to obliterate the vascular 
spaces. The embolization agent we prefer to use 
today is a polyvinyl alcohol sponge which remains 
within the body and permanently obliterates the 
abnormal vascular tumor bed." 
These arteriovenous malformations are present in 
growing children and the long term effect of treat- 
ment can only be assessed over a period of years. For 
example, excessive growth of a leg may be associated 
with the presence of soft tissue vascular malforma- 
tion. In order to determine whether or not the 
embolization procedure has adequately reduced the 
malformation, subsequent growth of the legs must be 
monitored carefully until the child's normal growth 
period is completed. 
Dr. Murphy added, "In the majority of cases we 
have treated, the results have been most gratifying. 
Large, deforming, and sometimes intermittently 
bleeding lesions have been well controlled for a 
period of several years, eliminating the need for 
radical surgery. We are currently following six pa- 
tients in various stages of this embolization therapy 
program who are being treated for a variety of 
lesions." With the results already evident, Dr. Stanley 
and Dr. Murphy feel that the technique of transcath- 
eter embolization of large chronic arteriovenous 
malformations in the trunk and limbs should be given 
consideration as the primary form of treatment when 
the dominant arterial feeder(s) can be clearly identi- 
fied and subselectively catheterized. This technique 




Dr. Mokhtar Gado, Mallinckrodt neuroradiologist, 
has utilized embolization techniques since 1971 to 
treat vascular malformations supplied by intracranial 
blood vessels, vessels of the head and neck, and tu- 
mors in the region of the pharynx, paranasal sinuses, 
tongue, face, or neck. 
He explained, "The technique depends upon the 
high blood flow in the abnormal vessels causing the 
emboli to lodge in them rather than in normal vessels. 
Therefore, more and more of the abnormal vessels are 
obliterated during the procedure." Dr. Gado expects 
new developments in this area to broaden the appli- 
cation of current procedures. 
Transhepatic Biliary Drainage 
Percutaneous Transhepatic Biliary Drainage is an 
interventional technique Dr. Philip Weyman has used 
to restore bile drainage in patients whose bile flow is 
inhibited by unresectable biliary obstruction, such as 
pancreatic cancer, metastatic disease, cancer of the 
biliary duct, or surgically unapproachable benign 
structures. The percutaneous procedure, performed 
under local anesthetic, involves threading a multi- 
holed catheter into the liver. The radiologist attempts 
to lace the catheter through the blockage and 
establish internal bile drainage to the duodenum. If 
the obstruction is impenetrable, the catheter estab- 
lishes a channel to drain bile externally. The patient 
can usually be discharged in a week to ten days. 
Dr. Weyman stresses that while surgery is still the 
primary corrective treatment, the percutaneous drain- 
age is a desirable palliative procedure to restore bile 
drainage and alleviate the affects of restricted bile 
flow. Occasionally radiologists establish transhepatic 
biliary drainage to improve the patient's condition 
preparatory to corrective surgery. In five months, Dr. 
Weyman has installed two external and three internal 
biliary drainage catheters. 
Whether these various interventional procedures 
serve as complements to surgery, options to surgery, 
or as potential primary treatment methods, they 
continue to widen the scope of patient treatment at 
the Mallinckrodt Institute of Radiology. 
New Computer Technique Expedites Patient Service 
In the present age there seems to be a computer for 
almost everything—from checking out groceries to 
doing library research. At Mallinckrodt Institute, 
computers play a powerful role in enhancing the 
quality of patient care and making the operation of 
the Institute more efficient and more productive. 
The Diagnostic Computer Section, under the direc- 
tion of Dr. Gilbert Jost and Rex Hill, M.S., is making 
a dramatic contribution to patient care through the 
use of optical reading techniques to track the points 
of each patient's progress through the Institute—from 
moment of arrival to moment of departure. "The 
technique, which is similar to the one used in food 
markets, is reliable, accurate, and quick to do," said 
Dr. Jost. A floor receptionist first logs the patient 
arrival time in the computer terminal by passing a 
computer wand over the x-ray requisition number. 
After the x-ray has been taken, the technologist 
registers completion time in a second terminal and 
sends the film to the quality control technologist, 
who, after approving film study quality, registers 
finish time in a third terminal. The receptionist then 
registers patient departure time in the computer. 
In order to provide a complete record of the 
patient's visit to the radiology department, the times 
of the following additional events are captured: 
1. When old films are matched with new and made 
available for reading by the radiologist. 
2. When films have been read and can be returned 
to the film library. 
3. When the radiologist's dictation is transcribed, 
the report signed and made available for distribution. 
According to Mr. Hill, statistics will be drawn from 
data accumulated on a continuing basis over a period 
of time. These statistics will aid in defining patterns 
and isolating problem areas. In addition, current 
information will be available on terminals at floor 
supervisors' desks. With pertinent data available and 
the names of patients who have waited over 30 
minutes on display, supervisors will be better able to 
direct attention to delays and schedule problems as 
they occur. This data will also be available at inquiry 
stations in the department. For example, a physician 
coming to the MIR film library area can be accurately 
informed of the status of a patient currently under- 
going an examination. 
"This application of a bar code technique is unique 
to Mallinckrodt," says Dr. Jost, "but it should prove 
to be a useful method for serving patients faster and 
more efficiently." 
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China Officials Visit Mallinckrodt 
"Everywhere we go we are met with 
smiling faces," Wang Chubin, head of the 
six-member delegation from the People's Re- 
public of China, said through their interpreter 
on a recent visit to Mallinckrodt. This first 
official visit was part of a St. Louis-Nanjing 
(Nanking) "sister city" relationship which was 
established in October, 1979, and is the 
nation's first such relationship with a Main- 
land Chinese city. 
Dr. Lewis J. Thomas, Jr., Director of the 
Washington University Computer Laboratory, 
was in charge of the tour which included 
activities at the medical center relevant to the 
interests of the group. Dr. Barry Siegel hosted 
a tour of Nuclear Medicine Facilities and Dr. 
Michel Ter-Pogossian demonstrated the PETT 
VI (positron emission transaxial tomograph) 
in the Division of Radiation Sciences. The 
PETT VI is the first in the PETT series to use 
cesium fluoride crystals as detectors, making 
it the fastest such detection system in the 
world for providing striking views into the 
living human brain. 
Zhou Bofan, a vice-chairman of the Nanjing 
Municipal Revolutionary Committee said that 
he was most impressed by the modern diag- 
nostic equipment such as the PETT and the 
CAT Scanner at Mallinckrodt Institute. 
Dr. Michel Ter-Pogossian, far right, is pictured at the PETT VI with three 
members of the Nanking delegation; translators, Shirley Cheng and 
Jing-Shiang Cheng of the Biomedical Computer Laboratory; Dr. Lewis J. 
Thomas, back left; and Mr. Edmund Greene, back right, of the 
Sister-City Committee. 
Dr. Barry Siegel describes activities within Nuclear Medicine to the 
visiting group and Mr. Frank Murphy of Mallinckrodt, Inc. 
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On the evening of June 23, the 
Washington University Alumni Club was 
the scene of a convivial gathering of 
MIR staff members and residents and 
their spouses to celebrate the completed 
residency training of Drs. Baron, Auf- 
derHeide, Bishop, Brinkley, Howard 
Glazer, Monsees, Oakley, and Totty, 
and the year's fellowship of Dr. Balfe. 
Following cocktails and hors d'oeuvres 
in the main lounge, the 90 guests were 
seated in the spacious dining room 
overlooking the Arch and the St. Louis 
riverfront. Dr. David Hardy, Chief- 
Resident, 1980-81, presided and Dr. 
Ronald Evens, after congratulatory 
remarks, presented each honoree with a 
commemorative brass plaque. 
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Dr. Robert Stanley presented four lectures at the 
5th International Meeting on Body CT in Rome, 
Italy, during May 19-23. 
Dr. James E. Marks was invited as a guest lecturer 
from the United States to the Third European Clinac 
Users Meeting held in the radiation center of Aalborg, 
Denmark on May 8-9. He spoke on "The Use of High 
Energy X-rays to Spare Normal Brain, Cranium and 
Soft Tissues" and "The Use of Electrons to Spare the 
Opposite Parotid for Selected Head and Neck Can- 
cers." 
Awards 
Dr. Todd H. Wasserman, Assistant Professor of 
Radiology in the Division of Radiation Oncology, has 
been awarded a first-year Junior Faculty Clinical 
Fellowship of the American Cancer Society for the 
period July 1, 1980-June 30, 1981. 
Dr. Joseph R. Simpson is a second-year recipient 
and Dr. Hywel Madoc-Jones has been awarded the 
fellowship for the third year. 
Panel Member 
Dr. G. Leland Melson discussed several aspects of 
residency training program as a panel member con- 
sidering Post Graduate Year-1 Options at the Annual 
Meeting of the Association of University Radiologists 
in Tucson, March 26. 
On May 19, Dr. Melson participated in a panel 
"Clinical Value of Ultrasonography in Urological 
Evaluation" where he discussed the relationship of 
ultrasound to other imaging techniques at the Annual 
Meeting of the American Urological Association in 
San Francisco. 
Scientific Exhibit 
Dr. Carlos A. Perez presented a scientific exhibit 
on "Cancer Therapy by Hyperthermia, Drugs, and 
Radiation" at the Third International Symposium, 






Dr. John Forrest ('71), Chief of Diagnostic Radiol- 
ogy at the University Hospital, UCSD, was a Visiting 
Professor in Chest Radiology, June 23-27. Dr. Forrest 
was Associate Professor of Radiology at Mallinckrodt 
until 1977. 
Dr. Bruce McClennan was a Visiting Professor at 
the University of Iowa April 28-29. 
Dr. Robert Stanley addressed the Greater Kans;j 
City Radiological Society and was a Visiting Professcr 
at the University of Kansas Medical Center and St. 





Dr. David Hardy has been appointed Chief Resi- 
dent for 1980-1981 and Dr. Harvey Glazer, Co-Chief 
Resident. Drs. Hardy and Glazer will be working 
closely with Dr. Ronald Evens and Dr. Lee Melson in 











Dr. Jill White, second year resident, has been 
elected the MIR Housestaff Representative to the 
Barnes Hospital Advisory Committee for the 1980 
academic year. 
CALENDAR OF EVENTS 
July 11-17, 1980 
AMERICAN SOCIETY OF RADIOLOGIC 
TECHNOLOGISTS 
Atlanta, Georgia 
July 13-19, 1980 
NATIONAL RADIOLOGIC TECHNOLOGY 
WEEK 
July 20-24, 1980 
AMERICAN MEDICAL ASSOCIATION 
Chicago, Illinois 
September 21-25, 1980 
AMERICAN COLLEGE OF RADIOLOGY 
New Orleans, Louisiana 
October 21-25, 1980 
AMERICAN SOCIETY OF THERAPEUTIC 
RADIOLOGISTS 
Dallas, Texas 
'November 16-21, 1980 
RADIOLOGICAL SOCIETY OF NORTH 
AMERICA 
Dallas, Texas 
Lectures - Symposiums 
Recent talks by Dr. Carlos A. Perez include: 
"Organization of Radiation Oncology in the Co- 
operative Groups," Clinical Cancer Investigation Re- 
view Committee, NIH, Bethesda, Maryland. 
"Frontiers of Cancer Research," at the First 
Community Conference on Cancer Nursing in Ft. 
Worth. 
"Carcinoma, of the Prostate," Southwestern Medi- 
cal School, Dallas. 
"Cancer of the Uterine Cervix" and "Cancer of the 
Prostate," Allegheny General Hospital, Pittsburgh. 
Dr. Robert Stanley was a member of the faculty 
for an Imaging Seminar at the Hospital of the 
University of Pennsylvania, Philadelphia, April 9-11. 
Dr. James E. Marks was a member of the faculty at 
a workshop sponsored by the University of North 
Carolina School of Medicine, March 14, in Chapel 
Hill, on Radiotherapy of Primary Malignant Gliomas. 
He spoke on "Review of Studies of Radiotherapy of 
Malignant Gliomas" and "Mechanisms of Evaluation 
of Response to Therapy." 
Dr. Patrick R. M. Thomas presented a talk on 
"Prospective Film Review in a Clinical Trial Involving 
Radiotherapy," at the American Society of Clinical 
Oncology, May 27, in San Diego. 
Dr. Robert Stanley addressed the American Asso- 
ciation of Anatomists in Omaha on April 30 during a 
forum in applied anatomy. 
Dr. Carlos A. Perez presented three lectures as a 
member of the faculty for a refresher course spon- 
sored by the University of Minnesota in Minneapolis, 
May 21-23. His subjects were: 
(1) Current Clinical Status of Hyperthermia, 
(2) Periaortic radiation and Prostate Cancer, and 
(3) Irradiation  of   Lung  Cancer Techniques and 
Results. 
Dr. Barbara B. Sterkel presented "Persistent Renal 
Activity Seen in Gallium Scans in Patients with 
Severe Hepatocellular Disease" at the 27th annual 
meeting of the Society of Nuclear Medicine, June 
24-27 in Detroit. 
Dr. Carlos A. Perez presented "Medical Aspects of 
Treatment Planning in Lung Cancer" at the American 




Drs. Theodore Phillips (left) and 
Todd Wasserman (right), speakers 
at the May 1 Cancer Workshop, 
with Dr. Carlos Perez, Director of 
the Division of Radiation Oncol- 
ogy. 
-*> 
At a recent Cancer Workshop, sponsored by the 
Division of Radiation Oncology of the Mallinckrodt 
Institute of Radiology, the subject of radiosensitizers 
and protector agents in cancer therapy was discussed 
by Dr. Todd H. Wasserman, Assistant Professor, 
Division of Radiation Oncology and Dr. Theodore L. 
Phillips, Professor and Chairman, Department of 
Radiation Oncology, University of California Medical 
Center, San Francisco. Dr. Wasserman, who worked 
with Dr. Phillips for three years prior to coming to St. 
Louis to join the staff of Mallinckrodt, was awarded 
the 1978 Resident Essay Award of the American 
Society of Therapeutic Radiology for his work with 
radiosensitizers. The subject of the workshop was the 
use of drugs that have no direct effect on cancer but 
modify the effect of ionizing radiation on cancer. 
Currently being investigated are two classes of 
drugs. The first type, those which sensitize tumor 
cells to radiation but do not sensitize normal tissues 
increase the selective ability of radiation to kill cancer 
cells without increasing the toxicity of radiation. 
Laboratory studies began on these drugs in the mid 
1970's and clinical trials in the United States began 
with a drug called Misonidazole in 1977. Conducted 
primarily through the Radiation Therapy Oncology 
Group, the trials were initially done at the University 
of California at San Francisco and are now being 
conducted at Washington University by the Division 
of Radiation Oncology. The sensitizers work by 
increasing the killing potential of radiation on cancer 
cells. Early clinical trials with Misonidazole on several 
hundred patients have offered promising results, 
although there are limitations of its use because of 
some drug related side effects on the nervous system. 
There is an increasing effort by chemists and phar- 
macologists to develop  other analogs of this drug 
which would lack the neurotoxicity. Currently there 
are nine active clinical Phase II trials involving 
Misonidazole underway in the United States and 
other trials underway in England, Canada, and other 
countries. Preliminary data suggests that despite the 
drug related toxicity, it can be given with high degree; 
of safety provided the total drug dose is limited. 
There is a suggestion that the use of the drug in 
conjunction with radiation increases cancer control of 
some tumors. 
The second area of new research in cancer therapy 
involves the use of drugs that protect the normal 
tissues from radiation without protecting the tumor. 
A series of compounds was originally developed by 
the Army at Walter Reed in Washington, D.C. in an 
attempt to protect troops from the threat of radia- 
tion sickness. The compounds did not perform as 
expected, but were discovered to protect normal 
tissues selectively against the effects of low dose 
radiation. As a follow-up of extensive laboratory 
work on one of these drugs, called WR-2721, and its 
protective effects against the bone marrow toxicity of 
chemotherapy agents, Drs. Phillips and Wasserman 
will participate in the first clinical trial of this drug in 
the United States sometime in the summer of 1980. 
The clinical staff of the Division of Radiation 
Oncology will be seeking participation of patients and 
referring physicians in the ongoing clinical trials of 
both the radiosensitizers and the radioprotectors. 
Dr. Phillips and Dr. Wasserman, who currently hava 
authored   several   papers  on   the  subject  of  their 
research, are advisors to the National Cancer Institute 
for development of further research in this area. The ^ 
were recently featured at a meeting organized as 
conference  on  radiation sensitizers and protector: 







Hyperthermia, high body temperature induced for 
therapeutic purposes, was first documented in 1866 
as effecting tumor regression, yet only in recent years 
with the development of new technology, has it 
become a viable treatment modality. Whether in- 
duced by hot water baths, ultra-sound waves, low 
radiofrequency waves, microwaves, heated blood per- 
fusions, or delivery of heated anesthetic gases to the 
lungs, hyperthermia temperatures of 107.6° to 113° 
tend to kill cancer cells but leave normal cells less 
affected. Cancer cells are more susceptible to heat 
because of their proliferating nature, poor circulation, 
poor nutrition, and characteristic inability to cool. In 
addition, cancer cells appear to be less able to repair 
from treatment by conventional methods if they are 
combined with hyperthermia. Radiotherapy, for ex- 
ample, is 40% to 60% more effective when combined 
with hyperthermia. 
In a recent television interview in the Division of 
Radiation Oncology of Mallinckrodt Institute, Dr. 
Carlos Perez, Director, Dr. Walter Kopecky, and one 
of their patients, Mr. Robert Siemer, discussed the 
procedure during an actual treatment session. Mr. 
.Siemer, who was being treated for cancer with 
microwave hyperthermia following a complete series 
of radiotherapy treatments, said he experienced only 
mild discomfort, initially from the insertion of 
probes, then from the five-minute period of heat rise. 
ewswBRian, observes Drs. Perez and 
paftjMBJ of  a  cancer patient for 
rmia. 
and finally from the ninety-minute duration of 
treatment. 
To begin the procedure, Dr. Perez inserted one of 
two small probes into the tumor core; the other, into 
superficial normal tissue. He explained that the 
probes are inserted without anesthetic because probe 
insertion is no more painful than anesthetic injection. 
Then, while the microwave transmitter was being 
aligned with the tumor and the controls were being 
set, Mr. Siemer described his treatment, "Other than 
an occasional mild burn and the discomfort of lying 
on a hard surface, I have found the procedure to be 
nearly painless." Dr. Kopecky, indicating dials on the 
monitor, added, "The gauges show the temperature 
being measured by the probes, but Bob alerts me if 
any particularly strong heat sensation occurs." Having 
nearly completed the hyperthermia treatment series, 
Bob Siemer spoke from experience, "I usually just 
relax and take a little nap." 
Microwave hyperthermia treatments are performed 
at Mallinckrodt Institute more frequently than at 
most other hospitals in the country, and approxi- 
mately 80% of the patients treated here in the last 
two years have experienced significant tumor reduc- 
tions. Dr. Perez stressed, however, that reduction 
does not translate to cure. "The procedure is still in 




To Help Predict Patient Response To Endocrine Therapy 
Hormone therapy has long been a treatment option 
for certain types of cancer but, until recently, its 
track record has been less than impressive—only one 
patient in three has benefited from hormonal manipu- 
lation. This statistic is due not to any major short- 
coming of hormonal therapy itself, but rather to the 
inability of physicians to predict which tumors will 
respond to this kind of management. Even after 
recent work which increased the response in breast 
cancer patients to between 50% to 60%, there was still 
a glaring need for a more reliable way to predict a 
tumor's hormone-responsiveness. Now, B.R. Rao, 
Ph.D., Mallinckrodt Institute Section of Cancer Biol- 
ogy, and his co-workers have given good reason for 
optimism regarding uncertain future of hormone 
therapy. Dr. Rao's new technique for detecting 
hormone receptors may well be the key to predicting 
accurately which tumors will respond to hormonal 
manipulation. 
The rationale behind hormone therapy is relatively 
simple. In certain normal cells, steroid hormones are 
essential for normal cell growth and protein synthesis. 
When cells undergo the transformation from normal- 
cy to malignancy, they may or may not retain this 
hormone dependency; if they do remain hormone- 
dependent, "ablative" hormone therapy (i.e., depriva- 
tion of necessary hormones) will interfere with their 
growth and eventually lead to tumor regression. 
One way of determining whether a tumor cell is 
hormone-dependent is to check for the presence of 
"hormone receptors" in its cytoplasm. This is more 
easily said than done, for current methods have been 
time-consuming and have yielded unacceptably high 
numbers of false-positive and false-negative cases. 
Dr. Rao and his associates have developed a 
technique which promises to simplify the identifica- 
tion of hormone-responsive tumors and improve the 
reliability of previous assay procedures. He uses 
fluorescein to label sex steroid hormones (specifical- 
ly, estrogen and progesterone). These labeled hor- 
mones are incubated with a tumor tissue sample, and 
count the number of cells to which they bind. 
This technique eliminates some of the technical 
impasse which has previously impeded the prediction 
of the response of tumor-to-hormone therapy. Much 
remains to be done, however. Investigators must 
closely follow those patients whom the assay has 
singled out as prime candidates for hormone therapy; 
such studies will reveal how closely the assay's 
prediction correlates with the patient's response to 
endocrine therapy. Also, using the Division's new 
flow cytometry facility (provided by contributions of 
the Advertising Federation of St. Louis), Dr. Rao and 
his associates will refine their procedures for quanti- 
fying the fluorescence and for counting the cells to 
which hormones will bind. If Dr. Rao's technique is 
as effective as it appears to be, it may contribute 
significantly to the treatment of breast, prostate, 
uterine, and renal cancers. 
RESIDENTS, FELLOWS & TRAINEES 1979-1980 
Back row, left: Drs. Balfe, Ling, Thaler, Totty, Brinkley, Scales, Vannier, Stein, Johnston, Bauer, Machefsky, Glazer, 
Chandra-Sekar. Center row: Drs. Yu, Glazer, Lenobel, Spies, Engelstad, AufderHeide, Bishop, Nicol, Miller, Monsees, 
Odrezin, White. Front row: Drs. Cintron; McDonald; Hardy; Sterkel; Melson; Baron, Chief Resident; Evens, 
Radiologist-in-Chief and Director of MIR; Oakley, Co-Chief Resident; Palmer; Kopen; Reed; Wahl. 
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Monte Carlo Seminar 
Dr. William Murphy spoke on 
"Forearm and Hand Arteriogra- 
phy" to the 125 participants. 
A view of Monte Carlo harbor. 
The second annual continuing medical education program, 
sponsored by the Mallinckrodt Institute of Radiology under 
the direction of Drs. Louis Gilula and William Murphy was 
held at the Loews Monte-Carlo hotel complex on the French 
Riviera, May 3-12. Dr. William McAlister was also a member of 
the faculty of distinguished American and European physi- 
cians who presented current concepts in musculoskeletal 
radiology and orthopedics. 
Following the symposium. Dr. Emily Smith visited 
Florence and Rome, Italy. Here she stands by the 
majestic doors to the Church of Santa Croce (Sacred 
Cross) in Florence. 
Dr. and Mrs. Charles Hobby of Valdosta, GA visit the 
Royal Palace of Prince Ranier and Princess Grace of 
Monaco. 
t 
Addresses Top Radiologic 
Technology Meeting 
Glenn   P.   Glasgow,  Ph.D.,  Assistant 
Professor  in  Radiation at Mallinckrodt 
Institute of  Radiology and Washington 
University, spoke on "Quality Assurance 
\ in Radiation Therapy" at the 52nd An- 
^ nual  Meeting of The American Society 
^ of Radiologic Technologists, July 11-17, 
■k \ in Atlanta. 
Dr. Glasgow joined the staff at Mallinckrodt 
Institute in 1974 as a Post-Doctoral Fellow. In 1975 
he became an instructor in Radiation Physics in 
Radiology, eventually moving to his present Assistant 
Professor post. He will be one of the 38 important 
health care professionals invited to address this 
scientific gathering of over 3,000 radiologic technol- 
ogists. 
The ASRT Atlanta Annual Meeting will provide 
educational opportunity to diagnostic radiographers, 
radiation therapy technologists, nuclear medicine 
technologists, and diagnostic medical sonography 
technologists from across the United States. 
Also offered at this professional gathering will be 
scientific displays, 32 symposia and seminars, and 
over 100 commercial exhibits. 
Dr. Barry A. Siegel presented a talk on "Radio- 
nuclide Renal Studies" at the annual meeting of the 
Technologists' Section of the Society of Nuclear 
Medicine, February 6-8, in Louisville, Kentucky. 
Deborah Christensen, C.N.M.T., was awarded first 
prize in the Scientific Papers Division for her presen- 
tation, "A Technique for Performing Simultaneous 
Ventilation-Perfusion Studies Utilizing Kr-8/M gas 
and Tc-99m MAA." 
TECHNO 
Authors Nuclear X-ray Atlas 
Radionuclide Imaging Artifacts, an atlas of nuclear 
x-ray images compiled by Donald R. Bernier, 
C.N.M.T., of the Nuclear Medicine Division of Mal- 
linckrodt Institute of Radiology and L. David Wells, 
C.N.M.T., of the Nuclear Medicine Division at Univer- 
sity Community Hospital in Tampa, illustrates un- 
usual problems associated with radionuclide imaging / 
The authors intend for the book to serve as both an 
educational document and a practical reference tool 
when technical problems occur. They hope that 
sharing these images will result in an overall improve- 






Norman Hente, R.T., lectured on "Preparing Scien- 
tific Exhibits" at the March meeting of the 7th 
District (Therapy) MSRT. He also spoke on "Photog- 
raphy in a Radiology Department" at the Gateway 
Chapter regional meeting of the Biological Photog- 
raphers Association held at MIR on March 22. 
Opposite page 
Barbara Hente demonstrates her technique of chest compres 
sion on "Resusci-Annie" while Norm Hente practices rescu. 
breathing. This special recording mannequin records hov 
much air is being blown into the victim's lungs and beeps if tht. 
student's hands are placed at a spot on the chest that woul( 
cause a cracked rib. Lights flash to indicate too much pressun 
applied. 1 
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CPR Workshop at MIR 
Eleven MIR employees were among 28 members of 
the 4th District of the Missouri Society of Radiologic 
Technologists who participated in a two-day work- 
shop in April leading to certification in CPR (cardio- 
pulmonary resuscitation) by the St. Louis Heart 
Association. Linda Kratz, R.N., of the MIR nursing 
staff was one of six certified instructors. The seminar 
l(7 E.C.E. points) included a slide lecture, movie, 
practical demonstrations, and hands-on experience. 
The training combines a procedure of chest com- 
pression and mouth-to-mouth breathing to keep 
blood and oxygen flowing through the body until the 
victim can receive more sophisticated cardiac care in 
an ambulance or hospital. 
High school senior, Cynthia Hegg with her prize-winning 
myeloma exhibit. 
Cynthia A. Hegg, a senior at Parkway West High 
School in St. Louis County, received top honors at 
the 1980 Monsanto/Post Dispatch Greater St. Louis 
Science Fair, for her research into the effects of a 
number of anticancer agents on a murine myeloma 
that closely parallels human multiple myeloma. Dur- 
ing five months of collaborative work with Mr. Dean 
Coulter in the laboratory of Dr. Fred Valeriote in the 
MIR Section of Cancer Biology she compared life- 
spans of treated tumor-bearing mice with those of 
untreated controls, while simultaneously measuring 
the toxicity of the drug dosages in normal mice. 
Protocols based on positive results of these and other 
studies will be developed at the Washington Univer- 
sity Medical Center over the next few years. 
Cynthia's exhibit, on display at the Museum of 
Science until Spring, 1981, reflects the analytical 
thought, scientific content, and research excellence 
stressed by the awarding institutions. Among her 
awards were a $4000 scholarship from Monsanto, the 
Curator's Scholarship for Tuition and Fees from the 
University of Missouri, and a $200 scholarship from 
the Medical Society of Greater St. Louis. In addition, 
Cynthia received the Blue Award in the Honors 
Division of the Science Fair and certificates of 
achievement from the American Cancer Society and 
the United States Air Force. 
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In her nature classes at St. Louis Children's Hospital, Dorothy Evans 
combined her love of gardening with her love of the young patients. 
"Our 
w She Had Magic 9? 
I met Dorothy Evans only a few months ago, when 
she was a patient in the Division of Radiation 
Oncology at Mallinckrodt Institute. I found myself 
thinking about her a great deal. There was some 
special quality about her-a certain zest for life and 
loving in her eyes-that had touched my heart and my 
imagination. I saw her in the midst of young 
professional women from the hospital staff, laughing 
mischievously, her eyes sparkling with good humor 
and warmth; I saw her talk about her "greenhouse" 
project at St. Louis Children's Hospital with the 
affection of a parent; I saw her look at John, her 
husband of 39 years, with real devotion and under- 
standing. I saw her radiantly happy as she visited with 
her son, John who was to receive his Ph.D. in Public 
Health from Harvard University in late spring; I saw 
her interest quicken as someone mentioned one of 
her many friends, whether it be her daily walking 
partner (3 to 5 miles each morning), a devoted 
neighbor, or a long-time associate with volunteers at 
Missouri Botanical Garden. I also saw Dorothy 
sleeping in a hospital bed, her husband sitting quietly 
beside her, and hovering in the ceiling a brightly 
colored enormous helium balloon bedecked with 
multi-colored ribbons and bearing the greeting, 
"Happy Easter." Dorothy died of multiple myeloma 
on April 21, 1980. 
Three years before her death, Dorothy played a 
fast game of tennis four times a week, walked 13 
miles to the Arch from her home in Kirkwood, and 
during her 12 years as a Volunteer Nature Therapist at 
St. Louis Children's Hospital, Dorothy touched the 
lives of many young patients, combining in one 
project her love of nature and gardening with her love 
of children. 
In the beginning, Dorothy had only a few plants to 








plants and wild flowers for the hospital-bound chil- 
dren from the Evans' farm in St. Francois County. 
Through the years, as a result of her tireless efforts 
and in spite of setbacks caused by lack of space, her 
project grew from a modest roof-top vegetable garden 
to a real greenhouse in which to hold her classes. 
Construction   was   done   by   John   Evans   and   his 
neighbors and associates; Huntleigh Hills Garden Club 
contributed  time  and   money;  Dorothy's   Alumnae 
Club  of  Stephens'  College   provided  the sink; and 
jnding came from grateful parents of hospitalized 
:ungsters. The greenhouse, dedicated in November 
79, was the story of love, labor, and determination 
1 the part of one Dorothy Evans—indeed, a dream 
lat came true. 
Three years ago,  Dorothy experienced severe rib 
lain  during a  tennis game—the first indication of 
nultiple   myeloma, a  bone  marrow malignancy.   In 
iis disease the malignant plasma cells in the bone 
arrow cause many areas of  bone to be resorbed, 
ading to soft and fragile bones and a high incidence 
pathologic fractures. 
In her valiant fight against cancer, Dorothy under- 
went a program of chemotherapy and spinal surgery, 
and multiple courses of radiotherapy in the Division 
if Radiation Oncology at Mallinckrodt Institute of 
Radiology. Even after suffering a loss of hearing from 
, tumor in the nerve center at the base of the skull, 
Dorothy continued to conduct her weekly classes at 
Children's Hospital until December 1979. 
Just as during the years Dorothy provided therapy 
to many children through her patience, love, and 
knowledge of plant and gardening, the example of her 
own life of courage and determination became 
therapy to people around her, inspiring others to be 
brave and strong. We are grateful for having known 
her. 
"Word Of Comfort" 
Fred Bingaman with Joy Van Dyke awaiting an X-ray on 
the fifth floor of Mallinckrodt. 
"Most children like grandfathers," says Fred Bing- 
aman, a 77-year-old grandfather, who has been a St. 
Louis Children's Hospital volunteer transporting chil- 
dren for pediatric X-ray at Mallinckrodt for four 
years. He feels that the "grandfather image" helps 
him in what he considers the most important aspect 
of his job—comforting and reassuring frightened 
children. The measure of Mr. Bingaman's success is 
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'Teaching Goes Or 
During  a  spring  power failure at the  Medi 
Center, Dr. Robert C. McKnight showed ingenu 
persistence, and dedication as he utilized 
nearest available window light for reviewing < 
diovascular films with radiology residents, 
Floyd Scales, left, and Michael Vannier, cei 
(Photo by Dr. William Totty) 
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